𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Correlation between Extreme Drug Resistance Assay and Response to Primary Paclitaxel and Cisplatin in Patients with Epithelial Ovarian Cancer

✍ Scribed by Gamal H. Eltabbakh; M.Steven Piver; Ronald E. Hempling; Fernando O. Recio; Shashikant B. Lele; David L. Marchetti; Trudy R. Baker; Leslie E. Blumenson


Book ID
112247459
Publisher
Elsevier Science
Year
1998
Tongue
English
Weight
67 KB
Volume
70
Category
Article
ISSN
0090-8258

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Extreme drug resistance assay and respon
✍ Eltabbakh, Gamal H. πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 2 views

## Background and Objectives: The extreme drug resistance (EDR) assay is an in vitro chemoresistance assay performed on tumor samples grown in culture and is claimed to predict drugs unlikely to produce response. Its clinical value in patients with epithelial ovarian cancer (EOC) has recently been

Low drug resistance to both platinum and
✍ Koji Matsuo; Virginia K. Bond; Michele L. Eno; Dwight D. Im; Neil B. Rosenshein πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 French βš– 216 KB πŸ‘ 1 views

## Abstract The objective of this study was to evaluate the role of an __in vitro__ drug resistance assay to platinum and taxane in the management of advanced epithelial ovarian, fallopian and primary peritoneal cancer. All patients with FIGO Stage IIIc and IV who received postoperative chemotherap

Role of salvage chemotherapy with topote
✍ Ghamande, Sharad A.; Piver, M. Steven πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 56 KB πŸ‘ 2 views

## Background and Objectives: We assessed the role of salvage chemotherapy with topotecan and cisplatin in patients with platinum-and paclitaxel-resistant advanced and recurrent ovarian or primary peritoneal cancer, based on the reported in vivo and in vitro synergism between these two drugs. Meth